

DRUG SAFETY NOTICE

Supply Update

DRUG NAME/STRENGTH/FORM:

Trurapi 100 units/ml solution for injection pre-filled pen

- SWB will be initiating Trurapi® in place of NovoRapid® for new patients.
- If clinically appropriate, patients may be switched from NovoRapid® to Trurapi®
- **Trurapi and Novorapid are not interchangeable!**

ALTERNATIVE

- Trurapi® is an insulin aspart biosimilar manufactured by Sanofi.
- Trurapi® has a 30% lower NHS list price vs. NovoRapid® pre-filled pens and cartridges and 15% lower NHS list price vs. NovoRapid® vials.

ADVICE

- Similar PK/PD profiles (T1DM), efficacy, safety, and tolerability (T1DM and T2DM)⁹⁻¹⁰
- Trurapi® (insulin aspart) is supported for local use and recommended as the preferred brand of insulin aspart in place of NovoRapid® for new patients in view of the cost to the NHS.
- The Trurapi® pre-filled pen is a SoloStar device (the same as all other Sanofi devices).
- Trurapi® is also available in vials and cartridges. Please see SPCs for further details.
- All insulin products must be prescribed by brand name.
- Trurapi® is different in colour to NovoRapid®
- Trurapi® and NovoRapid® cartridges are different sizes so are not interchangeable.
- The Trurapi cartridges should only be used with the following pens:
 - JuniorSTAR - which delivers Trurapi in 0.5-unit dose increments.
 - AllStar PRO which delivers Trurapi in 1.0-unit dose increments.
- Transferring a patient from NovoRapid to Trurapi can be done unit-to-unit based on the previous fast-acting insulin dose.
- Monitoring requirements are the same as with NovoRapid®
 - When transferring from other insulin medicinal products, adjustment of the Trurapi® dose and the dose of the basal insulin may be necessary. Trurapi® has a faster onset and a shorter duration of action than soluble human insulin. Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter.
- NovoRapid® will appear as Trurapi® on Unity.

ACTIONS


- Refer to the BNF and BNFc for full prescribing guidelines.
- All new patients requiring insulin aspart should be initiated on Trurapi®
- If clinically appropriate, patients may be switched from NovoRapid® to Trurapi®

- Patients who are attending for an annual review as an opportunistic switch where clinically appropriate.

Key Documents

1. Insulin Aspart - [BNF](#) - [BNFc](#)
2. Trurapi® 100 units/ml solution for injection in pre-filled pen - [SmPC](#) - [PIL](#)
3. Trurapi® 100 units/ml solution for injection in cartridge - [SmPC](#) - [PIL](#)
4. Trurapi® 100 units/ml solution for injection in vial - [SmPC](#) - [PIL](#)
5. Sanofi Campus - [TRURAPI® ▼ \(INSULIN ASPART 100 UNITS/ML\)](#)
6. Trurapi® Prescribing information via SANOFI - [TRURAPI® ▼ \(INSULIN ASPART 100 UNITS/ML\)](#)
7. Trurapi® Slides via SANOFI - [Slide Deck](#)
8. Trurapi® FAQ via SANOFI - [FAQ](#)
9. Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
10. Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.

Trurapi Solostar Pen



Trurapi Cartridge



Trurapi Vials



**FOR FURTHER INFORMATION CONTACT YOUR WARD BASED PHARMACY TEAM
OR
THE PHARMACY DEPARTMENT (CITY ext.5263; SANDWELL ext.3783).
OUT OF HOURS CONTACT THE ON-CALL PHARMACIST**

DATE OF ISSUE: 05/03/2024

REFERENCE NUMBER: 01-0324